Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries
| Autor: | Sumitra Thongprasert, Mercedes Liliana Dalurzo, Nirush Lertprasertsuke, Bojan Zaric, Ahmed Rabea, Fred R. Hirsch, Marileila Varella-Garcia |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms medicine.medical_treatment MEDLINE Developing country 030204 cardiovascular system & hematology Targeted therapy 03 medical and health sciences 0302 clinical medicine Internal medicine Biomarkers Tumor medicine Humans Precision Medicine Personalized therapy Intensive care medicine Lung cancer Developing Countries business.industry General Medicine Precision medicine medicine.disease Low and middle income countries 030220 oncology & carcinogenesis Biomarker (medicine) business |
| Zdroj: | American Society of Clinical Oncology Educational Book. :403-408 |
| ISSN: | 1548-8756 1548-8748 |
| Popis: | There have been many important advances in personalized therapy for patients with lung cancer, particularly for those with advanced disease. Molecular testing is crucial for implementation of personalized therapy. Although the United States and many Western countries have come far in the implementation of personalized therapy for lung cancer, there are substantial challenges for low- and middle-income countries (LMICs). Globally, the LMICs display great heterogeneity in the pattern of implementation of molecular testing and targeted therapy. The current review presents an attempt to identify the challenges and obstacles for the implementation of molecular testing and the use of targeted therapies in these areas. Lack of infrastructure, lack of technical expertise, economic factors, and lack of access to new drugs are among the substantial barriers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|